Drug-drug interaction between cyclosporine and agents affecting calcium-dependent lymphocyte proliferation.
Colombani
P M
PM
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
Bright
E C
EC
Wells
M
M
Hess
A D
AD
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D002478:Cells, Cultured; D003524:Cyclosporins / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects*; D010879:Piperazines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D013449:Sulfonamides / Q000494:pharmacology; D014268:Trifluoperazine / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology
D002121:Calcium Channel Blockers; D003524:Cyclosporins; D007093:Imidazoles; D007546:Isoquinolines; D010879:Piperazines; D013449:Sulfonamides; D014268:Trifluoperazine; C031938:calmidazolium; C017967:W 7; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D014700:Verapamil; D011493:Protein Kinase C